Publications and communications of Grégory Ehx

E. Kina, J.-P. Laverdure, C. Durette, J. Lanoix, M. Courcelles, Q. Zhao, A. Apavaloaei et al. "Breast cancer immunopeptidomes contain numerous shared tumor antigens." Journal of Clinical Investigation, 134, no. 1 (02 January 2024). doi:10.1172/JCI166740

M. V. R. Cuevas, M.-P. Hardy, J.-D. Larouche, A. Apavaloaei, E. Kina, K. Vincent, P. Gendron et al. "BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens." Genome Biology, 24, no. 1 (15 August 2023): 188. doi:10.1186/s13059-023-03029-1

N. Guilloy, M. A. Brunet, S. Leblanc, J.-F. Jacques, M.-P. Hardy, G. Ehx, J. Lanoix, P. Thibault, C. Perreault, and X. Roucou. "OpenCustomDB: Integration of Unannotated Open Reading Frames and Genetic Variants to Generate More Comprehensive Customized Protein Databases." Journal of Proteome Research, 22, no. 5 (05 May 2023): 1492 - 1500. doi:10.1021/acs.jproteome.3c00054

C. Ritacco, M. C. Köse, J. Courtois, L. Canti, C. Beguin, S. DUBOIS, B. Vandenhove et al. "Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells." iScience, 26, no. 3 (17 March 2023): 106085. doi:10.1016/j.isci.2023.106085

A. Trofimov, P. Brouillard, J.-D. Larouche, J. Séguin, J.-P. Laverdure, A. Brasey, G. Ehx et al. "Two types of human TCR differentially regulate reactivity to self and non-self antigens." iScience, 25, no. 9 (16 September 2022): 104968. doi:10.1016/j.isci.2022.104968

A. Apavaloaei, L. Hesnard, M.-P. Hardy, B. Benabdallah, G. Ehx, C. Thériault, J.-P. Laverdure et al. "Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers." Cell Reports, 40, no. 7 (16 August 2022): 111241. doi:10.1016/j.celrep.2022.111241

L. Canti, K. K. Ariën, I. Desombere, S. Humblet-Baron, P. Pannus, L. Heyndrickx, A. HENRY et al. "Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients." Cancer Cell, 40, no. 4 (11 April 2022): 335-337. doi:10.1016/j.ccell.2022.02.005

G. Ehx, J.-D. Larouche, C. Durette, J.-P. Laverdure, L. Hesnard, K. Vincent, M.-P. Hardy et al. "Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes." Immunity, 54, no. 4 (13 April 2021): 737-752. doi:10.1016/j.immuni.2021.03.001

L. Canti* , S. Humblet-Baron* , I. Desombere, J. Neumann, P. Pannus, L. Heyndrickx, A. Henry et al. "Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients." Journal of hematology & oncology, 14, no. 1 (2021): 174. doi:10.1186/s13045-021-01190-3

J. Courtois, C. Ritacco, S. DUBOIS, L. Canti, B. Vandenhove, L. SEIDEL, C. Daulne et al. "Itacitinib prevents xenogeneic GVHD in humanized mice." Bone Marrow Transplantation, 56 (2021): 2672-2681. doi:10.1038/s41409-021-01363-1

G. Ehx* , C. Ritacco* , M. HANNON, S. DUBOIS, L. Delens, E. WILLEMS, S. SERVAIS, P. Drion, Y. BEGUIN, and F. Baron. "Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis." American Journal of Transplantation, 21 (2021): 2662-2674. doi:10.1111/ajt.16505

C. Ritacco* , G. Ehx* , C. GREGOIRE, C. Daulne, E. WILLEMS, S. SERVAIS, Y. BEGUIN, and F. Baron. "High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation." Bone Marrow Transplantation, 56 (2021): 1828-1841. doi:10.1038/s41409-021-01221-0

A. Bolomsky, M. Vogler, M. C. Köse, C. A. Heckman, G. Ehx, H. Ludwig, and J. Caers. "MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents." Journal of hematology & oncology, 13, no. 1 (2020): 173. doi:10.1186/s13045-020-01007-9

J.-D. Larouche, A. Trofimov, L. Hesnard, G. Ehx, Q. Zhao, K. Vincent, C. Durette et al. "Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues." Genome Medicine, 12, no. 1 (2020). doi:10.1186/s13073-020-00740-7

N. Noronha* , G. Ehx* , M.-C. Meunier, J.-P. Laverdure, C. Thériault, and C. Perreault. "Major multilevel molecular divergence between THP-1 cells from different biorepositories." International Journal of Cancer, 147, no. 7 (2020): 2000-2006. doi:10.1002/ijc.32967

L. Delens, G. Ehx, J. SOMJA, L. Vrancken, L. Belle, L. SEIDEL, C. Grégoire et al. "In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease." Biology of Blood and Marrow Transplantation, 25 (2019): 204-215. doi:10.1016/j.bbmt.2018.10.007

G. Ehx and C. Perreault. "Discovery and characterization of actionable tumor antigens." Genome Medicine, 11, no. 1 (2019). doi:10.1186/s13073-019-0642-x

C. Grégoire, C. Ritacco, M. Hannon, L. SEIDEL, L. Delens, L. Belle, S. DUBOIS et al. "Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model." Frontiers in Immunology, 10 (2019): 619. doi:10.3389/fimmu.2019.00619

L. Dupont, G. Ehx, M. Chantry, C. Monseur, C. Leduc, L. Janssen, D. Cataldo et al. "Spontaneous atopic dermatitis due to immune dysregulation in mice lacking Adamts2 and 14." Matrix Biology, 70 (2018): 140-157. doi:10.1016/j.matbio.2018.04.002

G. Ehx, J. SOMJA, H.-J. Warnatz, C. Ritacco, M. HANNON, L. Delens, G. Fransolet et al. "Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice." Frontiers in Immunology, 9 (2018): 1943. doi:10.3389/fimmu.2018.01943

G. Ehx and F. Baron. "Immune recovery predicts survival after T-cell depleted allogeneic hematopoietic cell transplantation." Leukemia and Lymphoma, 58 (2017): 1774-1776. doi:10.1080/10428194.2017.1283688

G. Ehx, G. Fransolet, L. De Leval, S. D'Hondt, S. Lucas, M. Hannon, L. Delens et al. "Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects." Oncoimmunology (2017): 6:e1314425. doi:10.1080/2162402X.2017.1314425

L. Belle* , G. Fransolet* , J. Somja, M. BINSFELD, P. Delvenne, P. Drion, M. Hannon, Y. BEGUIN, G. Ehx* , and F. Baron*. "Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease." PLoS ONE, 11 (12 December 2016): 0167997. doi:10.1371/journal.pone.0167997

G. Fransolet* , G. Ehx* , J. SOMJA, L. Delens, M. Hannon, J. Muller, S. DUBOIS et al. "Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease." Journal of Hematology and Oncology, 9 (04 July 2016): 53. doi:10.1186/s13045-016-0281-2

S. SERVAIS, Y. BEGUIN, L. Delens, G. Ehx, G. Fransolet, M. Hannon, E. WILLEMS, S. Humblet-Baron, L. Belle, and F. Baron. "Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation." Expert Opinion on Investigational Drugs, 9 (11 May 2016): 957-972. doi:10.1080/13543784.2016.1182498

S. Göktuna, K. Shostak, T.-L. Chau, L. Heukamp, B. Hennuy, H. Q. Duong, A. LADANG et al. "The Prosurvival IKK-Related Kinase IKK« Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine." Cancer Research, 76 (2016): 2587-99. doi:10.1158/0008-5472.CAN-15-1473

M. HANNON, Y. BEGUIN, G. Ehx, S. SERVAIS, L. SEIDEL, C. Graux, J. Maertens et al. "Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning." Clinical Cancer Research, 21, no. 14 (15 July 2015): 3131-9. doi:10.1158/1078-0432.CCR-14-3374

G. Ehx* , M. Hannon* , Y. BEGUIN, S. Humblet-Baron* , and F. BARON*. "Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets." Oncotarget, 6 (2015): 43255-43266. doi:10.18632/oncotarget.6486

G. Ehx* , S. Gerin* , G. Mathy, F. Franck, H. C. Oliveira, A. E. Vercesi, and F. Sluse. "Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels." Lipids in Health and Disease, 13 (21 July 2014): 116. doi:10.1186/1476-511X-13-116

F. Baron, S. Humblet-Baron, G. Ehx, S. SERVAIS, M. HANNON, L. Belle, C. LECHANTEUR et al. "Thinking out of the box - New approaches to controlling GVHD." Current Hematologic Malignancy Reports, 9 (2014): 73-84. doi:10.1007/s11899-013-0187-9

A. Apavaloaei, Q. Zhao, L. Hesnard, K. Vincent, M.-P. Hardy, C. Durette, J. Lanoix et al. "Abstract 2993: Unmutated tumor antigens are abundant and contribute to tumor control in melanoma." Cancer Research, 83, 7_Supplement (04 April 2023): 2993-2993. doi:10.1158/1538-7445.am2023-2993

M.-V. R. Cuevas, M.-P. Hardy, J.-D. Larouche, A. Apavaloaei, E. Kina, K. Vincent, P. Gendron et al. "Abstract 2987: BamQuery: a new proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens." Cancer Research, 83, 7_Supplement (04 April 2023): 2987-2987. doi:10.1158/1538-7445.am2023-2987

E. Kina, J.-P. Laverdure, C. Durette, J. Lanoix, M. Courcelles, Q. Zhao, A. Apavaloaei et al. "Breast cancer immunopeptidomes contain numerous shared tumor antigens." Journal for ImmunoTherapy of Cancer, 10, S2 (November 2022): 1411. doi:10.1136/jitc-2022-sitc2022.1411

G. Ehx, K. Vincent, J.-D. Larouche, C. Durette, J.-P. Laverdure, J. Lanoix, E. Bonneil et al. "The tumor-specific antigen landscape of acute myeloid leukemia." Molecular Immunology, 150 (October 2022): 8. doi:10.1016/j.molimm.2022.05.035

G. Ehx, N. Nandita, C. Durette, J. Courtois, M.-P. Hardy, K. Vincent, J.-P. Laverdure et al. "Proteogenomic characterization of 5-azacytidine effects on acute myeloid leukemia immunopeptidome." HemaSphere, 6 (June 2022): 300-301. doi:10.1097/01.hs9.0000844488.25409.8e

M. V. Ruiz, A. Apavaloaei, Q. Zhao, M.-P. Hardy, S. Lemieux, C. Perreault, and G. Ehx. "BamQuery: A new proteogenomic tool to explore the immunopeptidome and validate tumor‐specific antigens." European Journal of Immunology, 51, S1 (August 2021): 60. doi:10.1002/eji.202170200

C. Ritacco, G. Ehx, L. Canti, S. DUBOIS, B. Vandenhove, S. SERVAIS, Y. Beguin, and F. Baron. "Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects." Biology of Blood and Marrow Transplantation, 26, no. 3 (01 March 2020): 168. doi:10.1016/j.bbmt.2019.12.028

G. Ehx, M. Hannon, S. DUBOIS, C. Daulne, P. Drion, Y. BEGUIN, S. Humblet-Baron, and F. BARON. "Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease." Biology of Blood and Marrow Transplantation, 23, no. 3 (March 2017): 365–S366. doi:10.1016/j.bbmt.2016.12.314

G. Ehx, M. HANNON, S. Dubois, C. Daulne, P. Drion, Y. Beguin, S. Humblet-Baron, and F. Baron. "Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease." Journal of Clinical Immunology, 37, no. 2 (10 February 2017): 197-266. doi:10.1007/s10875-017-0372-z

G. Ehx, G. Fransolet, L. de Leval, S. D'Hondt, S. Lucas, M. Hannon, L. Delens et al. "Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease." Biology of Blood and Marrow Transplantation, 22, no. 3 (March 2016): 393. doi:10.1016/j.bbmt.2015.11.917

L. Belle, G. Ehx, J. SOMJA, M. BINSFELD, M. Hannon, J. Caers, G. Fransolet, Y. Beguin, S. Humblet-Baron, and F. Baron. "Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease." Blood, 122, no. 21 (December 2013): 4474.

C. Beguin, O. Kwan, C. Ritacco, J.-C. Debray, E. Dejardin, S. Dubois, M. C. Köse et al. "TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease." Paper presented at Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France, 17 November 2023.

O. Kwan, L. Canti, G. Ehx, Y. Beguin, S. Humblet-Baron, and F. Baron. "Utilisation de techniques de biologie des systèmes pour une analyse détaillée de la réponse immunitaire au vaccin à ARN messager BNT162b2 chez les patients ayant bénéficié d'une allogreffe." Paper presented at 26ème Congrès Annuel de l'Association Française de Cytométrie 2023, Toulouse, France, 16 November 2023.

O. Kwan, L. Canti, G. Ehx, Y. Beguin, and F. Baron. "Systems vaccinology study of responses to BNT162b2 vaccine in allogeneic hematopoietic stem cell transplant recipients." Poster session presented at Séminaire des chercheurs Télévie 2024, Bruxelles, Belgium, 06 February 2024.

O. Kwan, L. Canti, G. Ehx, S. Humblet-Baron, and F. Baron. "Systems vaccinology study of responses to BNT162b2 vaccine in allogeneic hematopoietic stem cell transplant recipients." Poster session presented at GIGA Day 2023, Liège, Belgium, 04 September 2023.

G. Ehx, Claude Perreault, Pierre Thibault, Sébastien Lemieux, and Marie-Pierre Hardy. "Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof." WO2021207823A1 filed -1 Unspecified -001, and issued 21 October 2021.

N. Noronha, C. Durette, B. E Silva, J. Courtois, J. Humeau, A. Sauvat, M.-P. Hardy et al. "Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia." Eprint/Working Paper, United States: Cold Sprint Harbor Laboratory, 2022. https://orbi.uliege.be2268/298893. doi:10.1101/2022.12.02.518683

M. V. Ruiz Cuevas, M.-P. Hardy, J.-D. Larouche, A. Apavaloaei, E. Kina, K. Vincent, P. Gendron et al. "BamQuery: a proteogenomic tool for the genome-wide exploration of the immunopeptidome." Eprint/Working Paper, United States: Cold Spring Harbor Laboratory, 2022. https://orbi.uliege.be2268/298884. doi:10.1101/2022.10.07.510944